O. Bergis

发表

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

G. Griebel, C. Louis, J. Stemmelin, 2008, Pharmacology Biochemistry and Behavior.

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile

G. Griebel, O. Bergis, L. Rouquier, 2007, Neuropsychopharmacology.

GABAA and α-Amino-3-hydroxy-5-methylsoxazole-4-propionate Receptors Are Differentially Affected by Aging in the Rat Hippocampus*

O. Bergis, D. Ruano, J. Vitorica, 2000, The Journal of Biological Chemistry.

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab

D. Boulay, O. Bergis, M. Pruniaux, 2020, JACC. Basic to translational science.

SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation

G. Perrault, P. Soubrié, O. Bergis, 2003, Journal of Pharmacology and Experimental Therapeutics.

SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

G. Perrault, P. Soubrié, O. Bergis, 2003, The Journal of pharmacology and experimental therapeutics.

The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice

G. Griebel, D. Boulay, O. Bergis, 2010, Neuropsychopharmacology.

Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.

O. Bergis, C. Fankhauser, A. Grosset, 1996, The Journal of pharmacology and experimental therapeutics.

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia

G. Griebel, J. Stemmelin, O. Bergis, 2007, Neuropsychopharmacology.

The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents

G. Griebel, J. Stemmelin, O. Bergis, 2018, Scientific Reports.

Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.

O. Bergis, O. Curet, B. Scatton, 1998, Journal of affective disorders.

The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia

G. Griebel, D. Boulay, O. Bergis, 2016, Scientific Reports.

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia

G. Griebel, J. Stemmelin, D. Boulay, 2008, Pharmacology Biochemistry and Behavior.

The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents

G. Griebel, J. Stemmelin, O. Bergis, 2018, Scientific Reports.

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents

Thomas Bertrand, Bailin Zhang, Lionel Bert, 2015, Scientific Reports.

Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

S. Stahl, G. Griebel, J. Stemmelin, 2008, Neuropsychopharmacology.

Parallel Studies on Learning and LTP in the Dentate Gyrus

S. LaRoche, O. Bergis, V. Doyere, 1988 .

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

S. Stahl, G. Griebel, J. Stemmelin, 2008, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition

G. Griebel, O. Bergis, C. Cohen, 2011, Pharmacology Biochemistry and Behavior.

SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties

P. Soubrié, O. Bergis, J. Bockaert, 2002, Journal of Pharmacology and Experimental Therapeutics.

Enhancement of excitability and inhibitory processes in hippocampal dentate gyrus by noradrenaline: A pharmacological study in awake, freely moving rats

S. Sara, O. Bergis, Susan J. Sara, 1991, Neuroscience Letters.

Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model

Nicolas Moindrot, D. Boulay, O. Bergis, 2020, Molecular therapy. Methods & clinical development.

SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic Activity

R. Depoortère, G. Perrault, J. Simiand, 2003, Neuropsychopharmacology.

Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?

G. Griebel, D. Boulay, O. Bergis, 2013, Behavioural pharmacology.

SL65.0155: a novel 5-HT4 receptor partial agonist with potent cognition enhancing properties

O. Bergis, J. Terranova, R. Fischmeister, 2023 .